Collaboration for treating chronic kidney, cardiovascular and metabolic diseases

15 November 2024

Boehringer Ingelheim and the University of Pécs signed a cooperation agreement on 15 November. Under the agreement, the leading biopharmaceutical company and the university will conduct joint research, particularly in the areas of chronic kidney, heart, and metabolic diseases. The contract was signed by Yael Dassa Levinsky, the company's managing director, dr Attila Miseta, Rector of the University of Pécs, and dr András Fittler, Dean of the Faculty of Pharmacy at the University of Pécs.

Boehringer Ingelheim is working on groundbreaking therapies that are transforming the lives of present and future generations. The company is a market leader in research areas focusing on cardiovascular, kidney and metabolic diseases, oncology, respiratory diseases, immunology, mental health, and retinal health. The aim of the cooperation with the University of Pécs is for the company and the university to mutually support each other in innovation and educational activities, as well as collaborate on clinical trial programmes. In the latter area, they will primarily research chronic kidney, heart, and metabolic diseases in order to develop even more effective treatments and therapies.

The collaboration covers training, the development of diagnostic methods, and supporting the provision of practical educational knowledge to university students in the areas of pharmaceutical manufacturing and safe drug administration. Another goal of the cooperation is the joint research and development of data-driven healthcare and artificial intelligence solutions, as well as collaboration in clinical trial programmes.

Boehringer Ingelheim, headquartered in Ingelheim, operates 146 subsidiaries worldwide and employs more than 53,000 people in over 130 countries. Unlike most large, publicly traded pharmaceutical companies, the company founded in 1885 is privately owned, fully owned by the Boehringer, Liebrecht and von Baumbach families. The Hungarian subsidiary has been marketing Boehringer Ingelheim's pharmaceuticals and animal health products under the name Boehringer Ingelheim Hungarian Branch for 34 years. The University of Pécs is the first domestic university with which the company has officially partnered.

Source: University of Pécs

Photo: Szabolcs Csortos/University of Pécs